ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

ISHLT Consensus Statement on Strategies to Prevent and Manage Hemocompatibility Related Adverse Events in VAD Patients

Thursday, August 22, 2024

Submitted by

Mujtaba Mubashir

Source

Source Name: The Journal of Heart and Lung Transplantation

Source URL: https://www.jhltonline.org/article/S1053-2498(24)01646-2/fulltext

Author(s)

Ian B. Hollis, Douglas L. Jennings, Selim Krim, Van-Khue Ton, Anique Ducharme, Jennifer Cowger, Mary Looby, J.J. Eulert-Green, Neha Bansal, Ed Horn, Mirnela Byku, Jason Katz, C.J. Michaud, Indranee Rajapreyar, Patrick Campbell, Cassandra Vale,Richard Cosgrove, Jaime Hernandez-Montfort, Jessica Otero, Amanda Ingemi, Shashi Raj, Phillip Weeks, Richa Agarwal, Elena S. Martinez,Laurens F. Tops, Mustafa M. Ahmed, Amy Kiskaddon, Jamila Kremer, Mary Keebler, Ravi K. Ratnagiri

This consensus statement disseminated by the International Society for Heart and Lung Transplantation (ISHLT) focuses on the prevention and management of hemocompatability-related adverse events (HRAEs) in patients with durable, continuous-flow left ventricular assist devices (CF-LVAD). As survival in this group of patients continues to improve with advances in technology, HRAEs remain a concern. The ISHLT summarizes the literature in this field and shares several recommendations including management of antiplatelet agents, oral anticoagulation, management of high-risk patients, and management of bleeding or clotting events based on different existing devices.